Ksenia N. Koryanova

Ksenia N. Koryanova

Auto-generated profile, based on publicly available information

Ksenia N. Koryanova

Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University. 2. Russian Medical Academy of Continuing Professional Education

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AAA. S. Ametov
A. S. Ametov
ISIgor Shohin
Igor Shohin
ERE. A. Rogozhina
E. A. Rogozhina
TBT. G. Bodrova
T. G. Bodrova
MNM. E. Nevretdinova
M. E. Nevretdinova
SNS. M. Noskov
S. M. Noskov
Liraglutide is one of the analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently a priority treatment for diseases such as type 2 diabetes mellitus (mono- and combination therapy), obesity and overweight in the presence of at least one concomitant disease.The aim of the work was to assess the bioequivalence and comparability of the safety and tolerability profile of the drug Enligria® (liraglutide 6 mg/ml, Promomed RUS LLC, Russia) and the drug Saxenda® (liraglutide 6 mg/ml, Novo Nordisk AS, Denmark) after a single dose in healthy volunteers.Materials and methods. This study was an open-label, randomized, crossover comparative study to evaluate pharmacokinetic parameters, safety, tolerability and immunogenicity. The study comprised 26 healthy volunteers, 26 of whom were included in the bioequivalence assessment population. The study consisted of 2 periods, in each of which the volunteers received either the test drug (liraglutide at a single dose of 0.6 mg) or the reference drug (liraglutide at a single dose of 0.6 mg) once. The washout period between each dose was 7 days. Blood plasma samples were taken to determine the concentration of liraglutide in the range from 0 to 72 hours in each study period. Liraglutide concentrations were determined using a previously validated enzyme-linked immunosorbent assay (ELISA) method. A quantitative determination of antibodies to liraglutide in the blood serum samples was carried out using a microplate photometer and ready-made ELISA kits pre-validated by the manufacturer. The conclusion about the equivalence of the compared drugs was made based on the ratio of the parameters Cmax, AUC0→t and AUC0→t of the studied drug in relation to the reference one.Results. The pharmacokinetic parameters of the drugs were comparable to each other. The resulting 90% confidence intervals for the ratio of the values of Cmax, AUC0-t and AUC0-∞ of the Russian test and reference drug were 87.18–110.46, 84.40–104.11 and 86.69–103.22% respectively, which satisfied the criteria for assessing bioequivalence. The tolerability of the drugs in the volunteers was notified as good. The incidence of adverse events was comparable for the test and reference drugs. No serious adverse events were reported throughout the study. According to the results of the immunogenicity analysis, no antibodies to russian produced liraglutide were detected in the blood serum of the volunteers, which indicated the lack of the drug immunogenicity.Conclusion. During the study, the pharmacokinetic equivalence of the test and reference drugs was confirmed. The Russian drug Enligria® (liraglutide 6 mg/ml, Promomed RUS LLC, Russia) in comparison with a foreign drug Saxenda® (liraglutide 6 mg/ml, Novo Nordisk AS, Denmark).

9 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBDmitry Bakulin
Dmitry Bakulin
EMEvgeny Morkovin
Evgeny Morkovin
VPV. I. Petrov
V. I. Petrov
ASA. V. Strygin
A. V. Strygin
ACA. N. Chumachenko
A. N. Chumachenko
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.

9 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AAA. S. Ametov
A. S. Ametov
ISIgor Shohin
Igor Shohin
ERE. A. Rogozhina
E. A. Rogozhina
TBT. G. Bodrova
T. G. Bodrova
MNM. E. Nevretdinova
M. E. Nevretdinova
LBL. A. Balykova
L. A. Balykova
Semaglutide is a representative of analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently used in Russia for the treatment of type 2 diabetes mellitus (T2DM; in monotherapy and in combination therapy), including patients with obesity and overweight.The aimof the work was to conduct a comparative assessment of the physicochemical properties, a biological activity, bioequivalence and safety, including tolerability and immunogenicity, of the drug Quincent® (semaglutide, 1.34 mg/ml, a solution for a subcutaneous administration, Promomed Rus LLC, Russia) and the drug Ozempic® (semaglutide, 1.34 mg/ml, a solution for a subcutaneous administration, Novo Nordisk A/S, Denmark) when administered to healthy volunteers.Materials and methods.To assess the degree of similarity of the study drug Quincenta®(semaglutide, 1.34 mg/ml, a solution for a subcutaneous administration, Promomed Rus LLC, Russia) with a chemically synthesized active substance to the original (reference) drug Ozempic® (semaglutide, 1.34 mg/ml, a solution for a subcutaneous administration, Novo Nordisk A/S, Denmark), a comparative study of physicochemical properties and a biological activity was carried out. To assess the bioequivalence of the study drug and the reference drug, an open randomized parallel comparative study with the participation of healthy volunteers (n=54), 54 participants of which had been included in the population, was conducted. The volunteers were randomized into 2 groups in a 1:1 ratio, and received a single dose subcutaneously either of the study drug (domestic semaglutide at a dose of 0.5 mg) or the reference drug (foreign semaglutide at a dose of 0.5 mg). The mode of administration was in the morning on an empty stomach. A semaglutide concentration was determined in serum samples using a previously validated enzyme-linked immunosorbent assay (ELISA) method. A quantitative determination of antibodies to semaglutide in the human serum by ELISA was carried out with a microplate photometer using ready-made kits pre-validated by the manufacturer. The conclusion about the bioequivalence of the compared drugs was made using an approach based on the assessment of 90% confidence intervals for the ratios of the geometric mean values of the parameters Cmax, AUC(0–t)of semaglutide in the measurement original units.Results.The results of the comparative analysis of the study drug and the reference drug demonstrate the comparability of their physicochemical properties and biological activity. The results of the clinical study demonstrated the bioequivalence of the test drug and the reference drug. Thus, the pharmacokinetic parameters of the drugs were comparable to each other: the Cmaxvalue for the study drug was 42.088±8.827 ng/ml, for the reference drug Ozempic® it was 42.2556±7.84. Herewith, the half-life for the study drug and the reference drug was 168.39±39.47 and 157.99±28.57 hours, respectively. The resulting 90% confidence intervals for the ratio of the Cmaxand AUC0–tvalues of the study drug and the reference drug were 90.89–109.15 and 91.66–111.27%, respectively. The tolerability of the drugs in the volunteers was notified as good. No adverse events were recorded during the study. No serious adverse events were reported throughout the study. According to the results of the immunogenicity analysis, no antibodies to Russian-made semaglutide were detected in the blood serum of the volunteers, which indicated the lack of Results. The results of a comparative analysis of the study drug and the reference drug demonstrate the comparability of physicochemical properties and biological activity. The results of the clinical study demonstrated the bioequivalence of the study drug and the reference drug. Thus, the pharmacokinetic parameters of the drugs were comparable to each other: the Cmaxvalue for the study drug was 42.088±8.827 ng/ml, for the reference drug Ozempic® this figure was 42.2556±7.84. At the same time, the half-life for the study drug and the reference drug was 168.39±39.47 and 157.99±28.57 hours, respectively. The resulting 90% confidence intervals for the ratio of the Cmaxand AUC0–tvalues of the study drug and the reference drug were 90.89–109.15 and 91.66–111.27%, respectively. Tolerability of the drugs in volunteers was noted as good. No adverse events were recorded during the study. No serious adverse events were reported throughout the study. According to the results of the immunogenicity analysis, no antibodies to Russian-made semaglutide were detected in the blood serum of the volunteers, which indicated the lack of the drug immunogenicity.Conclusion.In the course of the study, the comparability of the physicochemical properties and biological activity of the studied Russian drug with the chemically synthesized active substance Quincenta® to the reference drug Ozempic® was confirmed: the activity range of the studied drugs was within 80–120% in relation to the standard sample of semaglutide. The bioequivalence and a similar safety profile, including the immunogenicity and tolerability of the Russian drug Quincenta® (semaglutide 1.34 mg/ml, Promomed Rus LLC, Russia) were shown in comparison with the foreign drug Ozempic® (semaglutide 1.34 mg/ml, Novo Nordisk A/C, Denmark).

23 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
EME. V. Makarova
E. V. Makarova
VZV. I. Zvereva
V. I. Zvereva
AMA. R. Makarova
A. R. Makarova
DBDmitry Bakulin
Dmitry Bakulin
ASA. S. Shuvaeva
A. S. Shuvaeva
A significant part of patients with diabetes purchase sugar-lowering drugs (SLDs) on their own in retail pharmacy chains, and the market trends they generate represent an urgent area for this study.The aim. To study the turnover of hypoglycemic drugs, including insulins, in the commercial sector of the pharmaceutical market of the Russian Federation (RF) for 2020–2024.Materials and methods. The data presented in this article is based on a periodic retail audit conducted by the biotech company IQVIA. The period of 5 years (2020–2024) was covered. Data collection covered 33,613 commercial pharmacies in all regions of the RF (about 43% of pharmacies).Results. In the period from 2020 to 2023, a relatively stable increase in the volume of SLDs purchases was revealed, with small fluctuations, while in 2024 a significant leap in consumption was recorded, both in quantitative (packages) and in value (rubles) terms. During the entire monitoring period, the total volume of SLDs and insulin purchases in the retail market segment increased by more than 1.2 times, from 41.98 million packages in 2020 to 51.70 million in 2024. At the same time, the total procurement budget (at wholesale prices) increased by more than 2 times — from 19.40 to 41.57 billion rubles. The average price per package has also increased significantly, from 462 rubles in 2020 to 923 rubles in 2024, an increase of 1.7 times, reflecting significant inflation in the commercial pharmaceutical sector. In general, the Russian pharmaceutical market offers all variants of modern innovative hypoglycemic drugs (dipeptidyl peptidase-4 inhibitors [iDPP4], sodium-glucose cotransporter 2 inhibitors [iSGLT2], glucagon-like peptide-1 receptor agonists [arGPP-1]), which, according to general trends, demonstrate a steady increase in turnover. Older and less effective sulfonylureas and their combinations with metformin still occupy a significant market share. arGPP-1 group showed the greatest growth in quantity (11 times) and value (5 times), mainly due to the entry of Russian semaglutide analogues into the market. Government measures and investments in import substitution have led to a significant increase in the share of Russian drugs in purchases. Despite the positive dynamics of Russian production, import substitution in the SLDs segment has not achieved complete success and accounts for less than half of the turnover of hypoglycemic drugs.Conclusion. The growth of SLDs consumption in the retail segment of the RF in 2020–2024 has been revealed, especially due to the innovative drugs arGPP-1 and iNGLT2. Despite maintaining the leading position of metformin, the consumption structure is shifting towards more expensive schemes. The increase in the total procurement budget and the average package price highlights the need to expand preferential security programs. Import substitution has increased significantly over the indicated period, however, the share of domestic drugs is still less than half of the turnover.

5 December 2019 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PYPolkovnikova Yulia
Polkovnikova Yulia
NSN. A. Severinova
N. A. Severinova
KKK. N. Koryanova
K. N. Koryanova
UTU. A. Tulskaya
U. A. Tulskaya
MGM. V. Grechkina
M. V. Grechkina

15 December 2022 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DZD. N. Zemskov
D. N. Zemskov
LBL. A. Balykova
L. A. Balykova
OROlga Radaev
Olga Radaev
KZK. Ya. Zaslavskaya
K. Ya. Zaslavskaya
ПБП. А. Белый
П. А. Белый
KKK. N. Koryanova
K. N. Koryanova
Since the beginning of the pandemic, repeated attempts have been made to develop etiotropic therapy for a novel coronavirus infection. Hydroxychloroquine, lopinavir/ritonavir, etc. derivatives were used as antiviral agents, however, they demonstrated a low efficiency and an insufficient safety. In this connection, other groups of drugs with a more effective and safe pharmacological profile are currently being actively used.The aimof the study was to analyze the literature references on the efficacy and safety of antiviral drugs for the COVID-19 treatment.Materials and methods.When searching for the materials for the review article writing, such abstract databases as PubMed, Google Scholar, e-Library were used. The search was carried out on publications for the period from January 2020 to september 2022. The key queries were: COVID-19, etiotropic therapy; immunological drugs; antiviral drugs; interferons.Results.Currently, there are various degrees of effective etiotropic drugs for the treatment of COVID-19 patients. The review has considered a few groups of drugs that are of interest from the point of view of etiotropic therapy: immunological drugs (anticovid plasma, the drugs based on antiviral antibodies, the drugs of recombinant interferons-α2 and -β1, as well as interferon inducers, i.e., the drugs based on double-stranded RNA sodium salt, and others); drugs that block the penetration of the virus into the cell (umifenovir); the drugs that disrupt the process of the viral replication (favipiravir, remdesivir, molnupiravir, nirmatrelvir/ritonavir).Conclusion.Synthetic antivirals, in particular favipiravir, molnupiravir, remdesivir, and nirmatrelvir/ritonavir, have the largest evidence base for their efficacy and safety. The search for new effective and safe etiotropic drugs for the treatment of COVID-19, as well as the collection and analysis of post-registration data on the drugs already used in clinical practice, continues.